Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-3,631
Closed -$806K 346
2023
Q2
$806K Sell
3,631
-86
-2% -$20K 0.12% 67
2023
Q1
$899K Buy
3,717
+926
+33% +$227K 0.13% 58
2022
Q4
$733K Buy
2,791
+149
+6% +$39.9K 0.12% 55
2022
Q3
$596K Buy
2,642
+39
+1% +$9.45K 0.24% 54
2022
Q2
$633K Sell
2,603
-98
-4% -$24K 0.21% 56
2022
Q1
$653K Sell
2,701
-622
-19% -$143K 0.18% 57
2021
Q4
$748K Buy
3,323
+193
+6% +$40.7K 0.2% 57
2021
Q3
$666K Buy
3,130
+1,515
+94% +$349K 0.19% 59
2021
Q2
$394K Buy
1,615
+126
+8% +$31K 0.14% 57
2021
Q1
$370K Sell
1,489
-152
-9% -$36.3K 0.14% 60
2020
Q4
$377K Buy
1,641
+98
+6% +$22.6K 0.17% 55
2020
Q3
$392K Hold
1,543
0.21% 53
2020
Q2
$364K Buy
1,543
+565
+58% +$129K 0.2% 54
2020
Q1
$198K Buy
978
+488
+100% +$107K 0.1% 72
2019
Q4
$118K Buy
490
+100
+26% +$22K 0.07% 89
2019
Q3
$75K Sell
390
-1,325
-77% -$254K 0.05% 89
2019
Q2
$316K Buy
1,715
+1,575
+1,125% +$282K 0.14% 70
2019
Q1
$27K Hold
140
0.02% 143
2018
Q4
$27K Buy
140
+65
+87% +$12.7K 0.02% 139
2018
Q3
$16K Buy
+75
New +$14.8K 0.01% 181
2018
Q2
Sell
-75
Closed -$13K 134
2018
Q1
$13K Buy
+75
New +$13.8K 0.01% 117

Other funds holding AMGN

Arlington Partners's AMGN Position: Q3 2023 in Review

Arlington Partners sold out of Amgen (AMGN) in Q3 2023, closing a stake of 3,631 shares — an estimated $806K sold.

Arlington Partners first reported a position in AMGN in Q1 2018 and held it in 21 quarters. The position peaked at $899K in Q1 2023. 2,501 funds tracked by Wall St. Rank hold AMGN as of Q3 2023.

  • Arlington Partners reported no remaining Amgen position as of Q3 2023 after selling out during the quarter.
  • Arlington Partners sold 3,631 Amgen shares in Q3 2023, an estimated $806K.
  • Arlington Partners first reported a position in Amgen in Q1 2018 and held it in 21 quarters.
  • Arlington Partners's Amgen position peaked at $899K in Q1 2023.
  • 2,501 funds tracked by Wall St. Rank held Amgen as of Q3 2023.

Based on Arlington Partners's 13F filing for Q3 2023, filed 24 Oct 2023.